Tag: 55686-94-7

55686-94-7, 2-Chloro-7-nitroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2-Chloro-7-nitroquinoxaline (27.8g, 133mmol), 1 -methyl-4-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 H-pyrazole (30.4g, 146mmol), 2M Na2C03 aqueous solution (66.3ml_, 133mmol) in ethylene glycol dimethyl ether (330ml_) were degassed with N2 for 15 minutes. Tetrakis(triphenylphosphine)palladium (0) (1.5g, 1 .33mmol) was added and the reaction mixture was heated at 100C for 7 hours. The reaction was poured into water. The precipitate was filtered off, taken-up with EtOAc, then filtered and dried under vacuum to give 31.4g (93%) of intermediate 4 (yellow solid). MP=231 C (DSC).

The synthetic route of 55686-94-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASTEX THERAPEUTICS LIMITED; SAXTY, Gordon; MURRAY, Christopher William; BERDINI, Valerio; BESONG, Gilbert Ebai; HAMLETT, Christopher Charles Frederick; JOHNSON, Christopher Norbert; WOODHEAD, Steven John; READER, Michael; REES, David Charles; MEVELLEC, Laurence Anne; ANGIBAUD, Patrick Rene; FREYNE, Eddy Jean Edgard; GOVAERTS, Tom Cornelis Hortense; WEERTS, Johan Erwin Edmond; PERERA, Timothy Pietro Suren; GILISSEN, Ronaldus Arnodus Hendrika Joseph; WROBLOWSKI, Berthold; LACRAMPE, Jean Fernand Armand; PAPANIKOS, Alexandra; QUEROLLE, Oliver Alexis Georges; PASQUIER, Elisabeth Therese Jeanne; PILATTE, Isabelle Noelle Constance; BONNET, Pascal Ghislain Andre; EMBRECHTS, Werner Constant Johan; AKKARI, Rhalid; MEERPOEL, Lieven; WO2011/135376; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55686-94-7,2-Chloro-7-nitroquinoxaline,as a common compound, the synthetic route is as follows.

To a suspension of nitro compound VI (14.36 g,68.5 mmol, 1 equiv.) in AcOEt (300 mE) is added SnCl2.2H20 (45.5 g, 239.9 mmol, 3.5 equiv.), then the reaction mixture is refluxed for 2 h. Afier cooling, 50% NaOH (6 equiv., 480 mmol) is added slowly at 00 C. and the reaction mixture is filtered on a silica gel pad and then eluted with hot acetone. After concentration, the residue is purified by recrystallisation with CHC13/petroleum ether to afford compound Had in the form of a yellow solid (9.65 g, 78%). ?H NMR (300 MHz, CDC13) oe ppm: 4.30 (brs, 2H), 7.03 (d, J=1.7 Hz, 1H), 7.15 (dd, J=8.8, 1.7 Hz, 1H), 7.85 (d, J=8.8 Hz, 1H), 8.47 (s, 1H). ?3C NMR (75 MHz, CDC13) oe ppm:107.2, 121.7, 130.3, 135.98, 140.3, 144.2, 147.7, 149.1. High-resolution mass (ESI): mlz calculated for [M+H] C8H7N3C1: 180.0329; mlz measured: 180.0326.

As the paragraph descriping shows that 55686-94-7 is playing an increasingly important role.

Reference£º
Patent; Institut Du Cerveau et de la Moelle Epiniere; Centre National de la Recherche Scientifique (CNRS (CNRS); Sorbonne Universite; Assistance Publique-Hopitaux de Paris; Institut National de la Sante et de la Recherche Medicale (INSERM); Universite Paris-SUD; Figadere, Bruno; Ferrie, Laurent; Le Douaron, Gael; Raisman-Vozari, Rita; Michel, Patrick; Sepulveda, Julia; (18 pag.)US2019/71438; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55686-94-7,2-Chloro-7-nitroquinoxaline,as a common compound, the synthetic route is as follows.

To a suspension of nitro compound VI (14.36 g,68.5 mmol, 1 equiv.) in AcOEt (300 mE) is added SnCl2.2H20 (45.5 g, 239.9 mmol, 3.5 equiv.), then the reaction mixture is refluxed for 2 h. Afier cooling, 50% NaOH (6 equiv., 480 mmol) is added slowly at 00 C. and the reaction mixture is filtered on a silica gel pad and then eluted with hot acetone. After concentration, the residue is purified by recrystallisation with CHC13/petroleum ether to afford compound Had in the form of a yellow solid (9.65 g, 78%). ?H NMR (300 MHz, CDC13) oe ppm: 4.30 (brs, 2H), 7.03 (d, J=1.7 Hz, 1H), 7.15 (dd, J=8.8, 1.7 Hz, 1H), 7.85 (d, J=8.8 Hz, 1H), 8.47 (s, 1H). ?3C NMR (75 MHz, CDC13) oe ppm:107.2, 121.7, 130.3, 135.98, 140.3, 144.2, 147.7, 149.1. High-resolution mass (ESI): mlz calculated for [M+H] C8H7N3C1: 180.0329; mlz measured: 180.0326.

As the paragraph descriping shows that 55686-94-7 is playing an increasingly important role.

Reference£º
Patent; Institut Du Cerveau et de la Moelle Epiniere; Centre National de la Recherche Scientifique (CNRS (CNRS); Sorbonne Universite; Assistance Publique-Hopitaux de Paris; Institut National de la Sante et de la Recherche Medicale (INSERM); Universite Paris-SUD; Figadere, Bruno; Ferrie, Laurent; Le Douaron, Gael; Raisman-Vozari, Rita; Michel, Patrick; Sepulveda, Julia; (18 pag.)US2019/71438; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider